News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
News
Policy
Ranbaxy Laboratories Gains in Mumbai After U.S. Withdraws Motion
October 9, 2008
|
1 min read
Twitter
LinkedIn
Facebook
Email
Print
Oct. 8 (Bloomberg) -- Ranbaxy Laboratories Ltd., the Indian drugmaker being purchased by Japan's Daiichi Sankyo Co., rose the most in almost three months after the U.S. withdrew a motion seeking to force the company to turn over audit reports.
Twitter
LinkedIn
Facebook
Email
Print
Legal
Regulatory
Asia
MORE ON THIS TOPIC
Neurodegenerative disease
Edgewise Takes a Hit as FDA Blocks Accelerated Path for Becker Muscular Dystrophy Drug
June 27, 2025
·
2 min read
·
Tristan Manalac
Collaboration
Alphabet Subsidiary Calico Colors In Up To $570M+ Aging Deal With China’s Mabwell
June 27, 2025
·
2 min read
·
Tristan Manalac
Government
Trump’s CDC Pick Says Vaccines Are Safe, Promises To Keep Them Available
June 26, 2025
·
2 min read
·
Tristan Manalac
Mergers & acquisitions
Lilly-Verve Proxy Filing Reveals Tumult After Departure of FDA’s Marks
June 26, 2025
·
4 min read
·
Annalee Armstrong
